Health
Should AstraZeneca Be Your Next Coronavirus Buy? – The Motley Fool
The drugmaker might well win the coronavirus vaccine race. What would that mean for its stock?
With no end in sight for the coronavirus pandemic, the world is seeing a frantic effort to develop a vaccine for the deadly virus. SARS-CoV-2, the coronavirus responsible for the COVID-19 disease, has taken close to 833,000 lives worldwide. Global recorded cases stand at 24 million, with 5.8 million — and more than 180,000 COVID-related deaths — in the U.S. alone.
AstraZeneca (NYSE:AZN), based in Cambridge, U.K., is working with the University of Oxford to develop its vaccine candidate, AZD12…
-
General18 hours agoQueensland government expands youth justice laws, David Crisafulli tells UN critics ‘you don’t control me’
-
General20 hours agoRestaurants on the brink as business failures plateau
-
General24 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General20 hours agoRegional house price growth outstrips capital cities